Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive muscle weakness. A research ...

ALS-associated RNA-binding proteins promote UNC13A transcription through REST downregulation - (https://www.embopress.org/doi ...

Researchers are one step closer to finding a common target for treating ALS - a fatal neurodegenerative disease that causes ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

UNC13A is an essential regulator of neurotransmitter release at synapses and is one of a number of pre-mRNAs that becomes mis-spliced due to loss of nuclear TDP-43 in disease.

Under the terms of the agreement, QurAlis granted Lilly an exclusive, worldwide license to develop and commercialize QRL-204 and other UNC13A-targeting compounds in exchange for an upfront payment ...

AcuraStem's iNeuroRx ® platform has successfully replicated UNC13A pathology in patient neurons, enabling the rapid development and testing of antisense oligonucleotides (ASOs).

UNC13A is a regulator of neurotransmitter release at synapses and is one of several pre-mRNAs that becomes mis-spliced due to loss of nuclear TDP-43 in disease.

UNC13A is an essential regulator of neurotransmitter release at synapses. In ALS and FTD, TDP-43 accumulates in the cytoplasm and no longer maintains its normal function controlling RNA metabolism ...

Acurastem Inc. has secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to facilitate the development of its UNC13A program toward clinical trials for ...

This latest funding will specifically support AcuraStem's continued efforts to advance its targeted therapeutic program for the UNC13A gene, using its iNeuroRx ® technology platform. iNeuroRx ...